The cases presented highlight the successful use of semaglutide, a GLP-1 receptor agonist, as an adjunct for weight loss in patients with ESRD who were candidates for renal transplantation but were previously ineligible due to obesity [10]. The gene discussed is GLP1R; the disease is Obesity.